Skip to main content
. 2020 Mar 24;13:605–612. doi: 10.2147/JPR.S237833

Figure 3.

Figure 3

Proportion of responders by eGFR at baseline (COMPOSE-1/COMPOSE-2 intent-to-treat population). *P value for the overall population calculated by Cochran-Mantel-Haenszel test; no statistical analyses were performed for subgroup comparisons.

Abbreviations: eGFR, estimated glomerular filtration rate; NAL, naldemedine, RI, renal impairment.